Results 241 to 250 of about 205,670 (312)

What Are the Limitations of Measuring Bladder Compliance, As the Sole Indicator of Future Risk to the Upper Urinary Tract and Renal Function? ICI‐RS 2025

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Maintenance of bladder filling and urinary storage at low intravesical pressures is fundamental to minimizing risk to the upper urinary tract. Bladder compliance describes the relationship between the bladder volume and the change in detrusor pressure during the filling phase of urodynamics.
Eric Rovner, Marcus J. Drake, Solomon Eskinder, Andrew Gammie, Sanjay Sinha, John Speich   +5 more
wiley   +1 more source

Impact of a low‐carbohydrate diet on cardiometabolic parameters in individuals with and without diabetes: An 8‐year longitudinal study within the ELSA‐Brasil cohort

Nutrition in Clinical Practice, EarlyView.
Abstract Background Low‐carbohydrate diets (LCDs) are widely adopted for metabolic management, but their long‐term cardiometabolic effects in diverse populations remain unclear. We aimed to evaluate the association between self‐selected moderate LCD adherence and cardiometabolic parameters in individuals with and without diabetes.
Leticia Batista de Azevedo, Haysla Xavier Martins, Oscar Geovanny Enriquez‐Martinez, Maria del Carmen Bisi Molina   +3 more
wiley   +1 more source

Association between decentralised clinical trial adoption and trial duration: a retrospective cross-sectional study of metabolic disease trials. [PDF]

BMJ Open
Lee SW, Cho KH.
europepmc   +1 more source

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial

Nutrition in Clinical Practice, EarlyView.
Abstract Background A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and ...
David F. Mercer, Constance Mubekapi‐Musadaidzwa, Bitten Kloster, Mark Berner‐Hansen, Anna Rydén, Palle Bekker Jeppesen   +5 more
wiley   +1 more source

When the Money Stops: A Safety-First Plan for Paused Clinical Trials. [PDF]

Clin Transl Sci
Smith D.
europepmc   +1 more source

New legal category of 'advanced regenerative medicine treatment' in Korea's amended regenerative medicine law: comparative lessons from Japan. [PDF]

Stem Cell Reports
Yoon J, Lee S, Kim JH.
europepmc   +1 more source

Safety and risk management in clinical trials for chronic wounds with tissue regenerative products. [PDF]

Ther Adv Drug Saf
Malikova MA, Roddy CM, Joyce NP, Cilley KN.   +3 more
europepmc   +1 more source

Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access. [PDF]

ESMO Real World Data Digit Oncol
Katsuya Y, Koyama T, Sato J, Okada M, Yamamoto N.   +4 more
europepmc   +1 more source